Literature DB >> 30520675

Peripheral Inflammation Accelerates the Onset of Mechanical Hypersensitivity after Spinal Cord Injury and Engages Tumor Necrosis Factor α Signaling Mechanisms.

Karmarcha K Martin1, Shangrila Parvin1, Sandra M Garraway1.   

Abstract

Previously, we showed that noxious stimulation of the tail produces numerous detrimental effects after spinal cord injury (SCI), including an earlier onset and increased magnitude of mechanical hypersensitivity. Expanding on these observations, this study sought to determine whether localized peripheral inflammation similarly impacts the expression of mechanical hypersensitivity after SCI. Adult rats received a moderate contusion injury at the thoracic level (Tl0) or sham surgery, and were administered complete Freund's adjuvant (CFA) or vehicle in one hindpaw 24 hours later. Examination of locomotor recovery (Basso, Beattie, and Bresnahan [BBB] score) showed no adverse effect of CFA. Mechanical testing with von Frey hairs was done at time-points ranging from 1 h to 28 days after CFA or vehicle treatment, and rats were sacrificed at 1, 7, or 28 days for cellular assessment. Unlike vehicle-treated SCI rats where mechanical hypersensitivity emerged at 14 days, CFA-treated SCI rats showed mechanical hypersensitivity as early as 1 h after CFA administration, which lasted at least 28 days. CFA-treated sham subjects also showed an early onset of mechanical hypersensitivity, but this was maintained up to 7 days after treatment. Cellular assessments revealed congruent findings. Expression levels of c-fos, tumor necrosis factor α (TNFα), TNF receptors, and members of the TNFα signaling pathway such as caspase 8 and phosphorylated extracellular related kinase (pERK) were preferentially upregulated in the lumbar spinal cord of SCI-CFA rats. Meanwhile, c-jun was significantly increased in both CFA-treated groups. Overall, these results together with our previous reports, suggest that peripheral noxious input after SCI facilitates the development of pain by mechanisms that may require TNFα signaling.

Entities:  

Keywords:  TNFα; central sensitization; chronic pain; mechanical hypersensitivity; peripheral inflammation

Mesh:

Substances:

Year:  2019        PMID: 30520675      PMCID: PMC6599394          DOI: 10.1089/neu.2018.5953

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  74 in total

1.  Sequential mRNA expression for immediate early genes, cytokines, and neurotrophins in spinal cord injury.

Authors:  M Hayashi; T Ueyama; K Nemoto; T Tamaki; E Senba
Journal:  J Neurotrauma       Date:  2000-03       Impact factor: 5.269

Review 2.  Epidemiology, demographics, and pathophysiology of acute spinal cord injury.

Authors:  L H Sekhon; M G Fehlings
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

3.  Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2.

Authors:  Valerie Fontaine; Saddek Mohand-Said; Noelle Hanoteau; Céline Fuchs; Klaus Pfizenmaier; Ulrich Eisel
Journal:  J Neurosci       Date:  2002-03-25       Impact factor: 6.167

Review 4.  Pain following spinal cord injury.

Authors:  P J Siddall; J D Loeser
Journal:  Spinal Cord       Date:  2001-02       Impact factor: 2.772

5.  An analysis of changes in sensory thresholds to mild tactile and cold stimuli after experimental spinal cord injury in the rat.

Authors:  A E Lindsey; R L LoVerso; C A Tovar; C E Hill; M S Beattie; J C Bresnahan
Journal:  Neurorehabil Neural Repair       Date:  2000       Impact factor: 3.919

6.  ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity.

Authors:  Ru-Rong Ji; Katia Befort; Gary J Brenner; Clifford J Woolf
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

Review 7.  Long-term potentiation in spinothalamic neurons.

Authors:  William D Willis
Journal:  Brain Res Brain Res Rev       Date:  2002-10

8.  Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia.

Authors:  Wei Guo; Shiping Zou; Yun Guan; Tetsuya Ikeda; Michael Tal; Ronald Dubner; Ke Ren
Journal:  J Neurosci       Date:  2002-07-15       Impact factor: 6.167

Review 9.  Cell death in models of spinal cord injury.

Authors:  Michael S Beattie; Gerlinda E Hermann; Richard C Rogers; Jacqueline C Bresnahan
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

10.  Instrumental learning within the spinal cord: IV. Induction and retention of the behavioral deficit observed after noncontingent shock.

Authors:  Eric D Crown; Adam R Ferguson; Robin L Joynes; James W Grau
Journal:  Behav Neurosci       Date:  2002-12       Impact factor: 1.912

View more
  4 in total

1.  Atrial Natriuretic Peptide and the Epithelial Sodium Channel Contribute to Spinal Cord Injury-Induced Polyuria in Mice.

Authors:  Xue-Song Sun; Xiao-Long Wang; Ming Bai; Chang Song; Douglas C Eaton; Qiang Yue; Karmarcha K Martin; Hui Cai; Sandra Garraway; Li-Hua Wang; He-Ping Ma
Journal:  J Neurotrauma       Date:  2022-05       Impact factor: 4.869

2.  Role of the CXCR4/ALK5/Smad3 Signaling Pathway in Cancer-Induced Bone Pain.

Authors:  Chong Peng; Xue-Tai Chen; Heng Xu; Li-Ping Chen; Wen Shen
Journal:  J Pain Res       Date:  2020-10-14       Impact factor: 3.133

3.  Spinal Cord Injury Increases Pro-inflammatory Cytokine Expression in Kidney at Acute and Sub-chronic Stages.

Authors:  Shangrila Parvin; Clintoria R Williams; Simone A Jarrett; Sandra M Garraway
Journal:  Inflammation       Date:  2021-08-21       Impact factor: 4.092

4.  Urolithin A as a Potential Drug for the Treatment of Spinal Cord Injuries: A Mechanistic Study Using Network Pharmacology Approaches.

Authors:  Chao Mao; HaoPeng Luan; ShuTao Gao; WeiBin Sheng
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-22       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.